## Elliott J Mufson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9306812/publications.pdf

Version: 2024-02-01

184

all docs

178 23,302 70 papers citations h-index

citations h-index g-index

184
184
16903
docs citations times ranked citing authors

148

#	Article	IF	CITATIONS
1	Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1 $\hat{a}$ e"Ch6). Neuroscience, 1983, 10, 1185-1201.	2.3	2,229
2	Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey. Journal of Comparative Neurology, 1983, 214, 170-197.	1.6	1,868
3	Insula of the old world monkey. III: Efferent cortical output and comments on function. Journal of Comparative Neurology, 1982, 212, 38-52.	1.6	940
4	Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 1372-1384.	3.1	854
5	Cortical projections arising from the basal forebrain: A study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience, 1984, 13, 627-643.	2.3	718
6	Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 2007, 68, 1501-1508.	1.1	676
7	Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology, 2002, 51, 145-155.	<b>5.</b> 3	639
8	Precursor form of brainâ€derived neurotrophic factor and mature brainâ€derived neurotrophic factor are decreased in the preâ€clinical stages of Alzheimer's disease. Journal of Neurochemistry, 2005, 93, 1412-1421.	3.9	614
9	Insula of the old world monkey. Architectonics in the insulo-orbito-temporal component of the paralimbic brain. Journal of Comparative Neurology, 1982, 212, 1-22.	1.6	603
10	Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. Neuroscience, 1984, 12, 669-686.	2.3	563
11	Insula of the old world monkey. II: Afferent cortical input and comments on the claustrum. Journal of Comparative Neurology, 1982, 212, 23-37.	1.6	515
12	Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Review of Neurotherapeutics, 2008, 8, 1703-1718.	2.8	493
13	Neuronal Cell Death Is Preceded by Cell Cycle Events at All Stages of Alzheimer's Disease. Journal of Neuroscience, 2003, 23, 2557-2563.	3.6	441
14	Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Annals of Neurology, 2001, 49, 202-213.	<b>5.</b> 3	397
15	TrkAâ€immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. Journal of Comparative Neurology, 1994, 350, 587-611.	1.6	321
16	Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain. Experimental Neurology, 1989, 105, 221-232.	4.1	271
17	Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. Journal of Chemical Neuroanatomy, 2003, 26, 233-242.	2.1	266
18	Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: Colocalization with cholinergic neurons. Journal of Comparative Neurology, 1989, 285, 196-217.	1.6	242

#	Article	IF	CITATIONS
19	Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. Journal of Comparative Neurology, 1999, 411, 693-704.	1.6	235
20	Down regulation of trk but not p75 <sup>NTR</sup> gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. Journal of Neurochemistry, 2006, 97, 475-487.	3.9	229
21	Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease Progression. Biological Psychiatry, 2010, 68, 885-893.	1.3	229
22	Thalamic connections of the insula in the rhesus monkey and comments on the paralimbic connectivity of the medial pulvinar nucleus. Journal of Comparative Neurology, 1984, 227, 109-120.	1.6	226
23	Entorhinal Cortex $\hat{I}^2$ -Amyloid Load in Individuals with Mild Cognitive Impairment. Experimental Neurology, 1999, 158, 469-490.	4.1	226
24	Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. Journal of Comparative Neurology, 2000, 427, 19-30.	1.6	225
25	Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2004, 63, 641-649.	1.7	212
26	The Role of Nerve Growth Factor Receptors in Cholinergic Basal Forebrain Degeneration in Prodromal Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2005, 64, 263-272.	1.7	210
27	î²-Amyloid Deposition and Functional Impairment in the Retina of the APPswe/PS1î"E9 Transgenic Mouse Model of Alzheimer's Disease. , 2009, 50, 793.		197
28	Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. Acta Neuropathologica Communications, 2017, 5, 8.	5.2	197
29	Loss of basal forebrain P75 <sup>NTR</sup> immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. Journal of Comparative Neurology, 2002, 443, 136-153.	1.6	195
30	Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica, 2012, 123, 13-30.	7.7	189
31	Differential Expression of Synaptic Proteins in the Frontal and Temporal Cortex of Elderly Subjects With Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2006, 65, 592-601.	1.7	183
32	Reduction of cortical TrkA but not p75 <sup>NTR</sup> protein in earlyâ€stage Alzheimer's disease. Annals of Neurology, 2004, 56, 520-531.	5.3	181
33	Reduction in p140-TrkA Receptor Protein within the Nucleus Basalis and Cortex in Alzheimer's Disease. Experimental Neurology, 1997, 146, 91-103.	4.1	175
34	Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Annals of Neurology, 2001, 49, 202-13.	5.3	171
35	Galanin immunoreactivity in the primate central nervous system. Journal of Comparative Neurology, 1992, 319, 479-500.	1.6	161
36	NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease. Experimental Neurology, 1989, 106, 222-236.	4.1	151

#	Article	IF	CITATIONS
37	Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochemical Research, 2002, 27, 1035-1048.	3.3	141
38	Cholinergic projections from the parabigeminal nucleus (Ch8) to the superior colliculus in the mouse: a combined analysis of horseradish peroxidase transport and choline acetyltransferase immunohistochemistry. Brain Research, 1986, 370, 144-148.	2.2	139
39	Distribution of galaninergic immunoreactivity in the brain of the mouse. Journal of Comparative Neurology, 2001, 434, 158-185.	1.6	136
40	Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. Journal of Neurochemistry, 2010, 113, 649-660.	3.9	130
41	Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology. Journal of Alzheimer's Disease, 2003, 5, 39-48.	2.6	129
42	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics, 2017, 14, 35-53.	4.4	128
43	Hippocampal plasticity during the progression of Alzheimer's disease. Neuroscience, 2015, 309, 51-67.	2.3	120
44	Galaninâ€like immunoreactivity within the primate basal forebrain: Differential staining patterns between humans and monkeys. Journal of Comparative Neurology, 1990, 294, 281-292.	1.6	119
45	Synaptic Change in the Posterior Cingulate Gyrus in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1073-1090.	2.6	112
46	Three-dimensional representation and cortical projection topography of the nucleus basalis (Ch4) in the macaque: concurrent demonstration of choline acetyltransferase and retrograde transport with a stabilized tetramethylbenzidine method for horseradish peroxidase. Brain Research, 1986, 367, 301-308.	2.2	111
47	Regional Selectivity of rab5 and rab7 Protein Upregulation in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 631-639.	2.6	110
48	Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology, 2014, 79, 172-179.	4.1	109
49	Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 102-110.	2.1	107
50	Age-related shrinkage of cortically projecting cholinergic neurons: A selective effect. Annals of Neurology, 1987, 22, 31-36.	5.3	104
51	$\hat{l}$ ±7 Nicotinic Receptor Up-regulation in Cholinergic Basal Forebrain Neurons in Alzheimer Disease. Archives of Neurology, 2007, 64, 1771.	4.5	103
52	Progression of Tau Pathology in Cholinergic Basal Forebrain Neurons in Mild Cognitive Impairment and Alzheimer's Disease. American Journal of Pathology, 2011, 179, 2533-2550.	3.8	101
53	Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease, 2013, 58, 92-101.	4.4	100
54	Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behavioural Brain Research, 2016, 311, 54-69.	2.2	99

#	Article	IF	CITATIONS
55	Tauâ€66: evidence for a novel tau conformation in Alzheimer's disease. Journal of Neurochemistry, 2001, 77, 1372-1385.	3.9	94
56	Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. Alzheimer's and Dementia, 2017, 13, 541-549.	0.8	94
57	Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 1401-1408.	3.9	93
58	Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease. Neurobiology of Aging, 2017, 59, 107-120.	3.1	93
59	Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly. Current Alzheimer Research, 2007, 4, 340-350.	1.4	91
60	Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Annals of Neurology, 1988, 24, 623-629.	5 <b>.</b> 3	90
61	Hippocampal ProNGF Signaling Pathways and $\hat{I}^2$ -Amyloid Levels in Mild Cognitive Impairment and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1018-1029.	1.7	89
62	Cholinergic forebrain degeneration in the APPswe/PS1î"E9 transgenic mouse. Neurobiology of Disease, 2007, 28, 3-15.	4.4	87
63	A Confocal Microscopic Analysis of Galaninergic Hyperinnervation of Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Brain Pathology, 1997, 7, 723-730.	4.1	86
64	Single-Cell Gene Expression Analysis: Implications for Neurodegenerative and Neuropsychiatric Disorders. Neurochemical Research, 2004, 29, 1053-1064.	3.3	84
65	Evidence for Alzheimer's disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Structure and Function, 2015, 220, 3143-3165.	2.3	83
66	Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology, 2011, 77, 39-47.	1,1	82
67	Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. Journal of Comparative Neurology, 1999, 411, 693-704.	1.6	80
68	Neuropathology of Mice Carrying Mutant APPswe and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway. Experimental Neurology, 2001, 170, 227-243.	4.1	79
69	Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment. Journal of Histochemistry and Cytochemistry, 2000, 48, 1627-1637.	2.5	77
70	Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiology of Disease, 2011, 41, 338-352.	4.4	77
71	Hippocampal Drebrin Loss in Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 216-219.	1.4	75
72	Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiology of Disease, 2014, 70, 32-42.	4.4	75

#	Article	IF	CITATIONS
73	Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla ( <i>Gorilla gorilla gorilla</i> ). Journal of Comparative Neurology, 2013, 521, 4318-4338.	1.6	74
74	Single cell gene expression profiling in Alzheimer's disease. NeuroRx, 2006, 3, 302-318.	6.0	71
75	Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiology of Aging, 2016, 42, 1-12.	3.1	69
76	Galaninergic Innervation of the Cholinergic Vertical Limb of the Diagonal Band (Ch2) and Bed Nucleus of the Stria terminalis in Aging, Alzheimer's Disease and Down's Syndrome (Part 1 of 2). Dementia and Geriatric Cognitive Disorders, 1993, 4, 237-243.	1.5	65
77	Preservation of Brain Nerve Growth Factor in Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2003, 60, 1143.	4.5	65
78	Galanin immunoreactivity within the primate basal forebrain: Evolutionary change between monkeys and apes. Journal of Comparative Neurology, 1993, 336, 31-39.	1.6	64
79	Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment. Frontiers in Neuroscience, 2015, 9, 430.	2.8	64
80	Reduction in TrkAâ€Immunoreactive Neurons Is Not Associated with an Overexpression of Galaninergic Fibers Within the Nucleus Basalis in Down's Syndrome. Journal of Neurochemistry, 2000, 74, 1185-1196.	3.9	63
81	YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology. Nature Communications, 2020, 11, 507.	12.8	62
82	Nerve Growth Factor Pathobiology During the Progression of Alzheimer's Disease. Frontiers in Neuroscience, 2019, 13, 533.	2.8	60
83	Nerve growth factor-like immunoreactive profiles in the primate basal forebrain and hippocampal formation. Journal of Comparative Neurology, 1994, 341, 507-519.	1.6	59
84	Superior Frontal Cortex Cholinergic Axon Density in Mild Cognitive Impairment and Early Alzheimer Disease. Archives of Neurology, 2007, 64, 1312.	<b>4.</b> 5	59
85	Staging of Alzheimer's Pathology in Triple Transgenic Mice: A Light and Electron Microscopic Analysis. International Journal of Alzheimer's Disease, 2010, 2010, 1-24.	2.0	59
86	Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: Colocalization with amyloid plaques. Neurobiology of Aging, 1994, 15, 621-627.	3.1	56
87	Galanin in Alzheimer Disease. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 137-156.	3.4	56
88	TRK-immunoreactivity in the monkey central nervous system: Forebrain. Journal of Comparative Neurology, 1994, 349, 20-35.	1.6	53
89	Galanin Fiber Hyperinnervation Preserves Neuroprotective Gene Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 885-896.	2.6	53
90	Cortical effects of neurotoxic damage to the nucleus basalis in rats: persistent loss of extrinsic cholinergic input and lack of transsynaptic effect upon the number of somatostatin-containing, cholinesterase-positive, and cholinergic cortical neurons. Brain Research, 1987, 417, 385-388.	2.2	52

#	Article	IF	Citations
91	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.8	52
92	Sex Differences in the Cholinergic Basal Forebrain in the <scp>Ts65Dn</scp> Mouse Model of <scp>D</scp> own Syndrome and <scp>A</scp> lzheimer's Disease. Brain Pathology, 2014, 24, 33-44.	4.1	51
93	Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 599-609.	2.6	50
94	Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons. Brain Research, 1991, 539, 19-30.	2.2	49
95	Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly. Journal of Alzheimer's Disease, 2016, 53, 1641-1652.	2.6	48
96	Primum non nocere: a call for balance when reporting on CTE. Lancet Neurology, The, 2019, 18, 231-233.	10.2	48
97	Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. Current Alzheimer Research, 2015, 13, 97-106.	1.4	47
98	Connections of the hippocampal formation in humans: II. The endfolial fiber pathway. Journal of Comparative Neurology, 1997, 385, 352-371.	1.6	45
99	Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease. Hippocampus, 2019, 29, 422-439.	1.9	45
100	Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: their depletion in Alzheimer's disease and morphologic alteration in non-demented elderly with numerous senile plaques. Brain Research, 1993, 625, 125-138.	2.2	43
101	Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains. Acta Neuropathologica, 1994, 87, 284-292.	7.7	43
102	Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: an in vitro autoradiographic analysis. Neuropharmacology, 2000, 39, 1404-1412.	4.1	43
103	Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiology of Aging, 2016, 37, 147-153.	3.1	43
104	Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Progress in Brain Research, 2006, 158, 197-222.	1.4	42
105	MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiology of Aging, 2011, 32, 1756-1764.	3.1	42
106	Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer's Disease. Neurodegenerative Diseases, 2014, 13, 151-153.	1.4	42
107	Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Current Alzheimer Research, 2015, 13, 35-52.	1.4	41
108	Galanin Fiber Hypertrophy within the Cholinergic Nucleus Basalis during the Progression of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 205-214.	1.5	40

#	Article	IF	CITATIONS
109	Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neuroscience Letters, 2010, 471, 129-133.	2.1	40
110	Resilience of Precuneus Neurotrophic Signaling Pathways Despite Amyloid Pathology in Prodromal Alzheimer's Disease. Biological Psychiatry, 2015, 77, 693-703.	1.3	38
111	<scp>HDAC</scp> 2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2019, 45, 380-397.	3.2	38
112	Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiology of Disease, 2018, 117, 125-136.	4.4	37
113	Neuroprotective Role for Galanin in Alzheimer's Disease. Exs, 2010, 102, 143-162.	1.4	37
114	Observations on choline acetyltransferase containing structures in the CD-1 mouse brain. Neuroscience Letters, 1988, 84, 7-12.	2.1	36
115	NPT088 reduces both amyloidâ $\in$ $\hat{\mathfrak{t}}^2$ and tau pathologies in transgenic mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 141-155.	3.7	36
116	Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 115-131.	2.6	36
117	Maternal choline supplementation differentially alters the basal forebrain cholinergic system of youngâ€adult Ts65Dn and disomic mice. Journal of Comparative Neurology, 2014, 522, 1390-1410.	1.6	35
118	Early Alzheimer's disease–type pathology in the frontal cortex ofÂwild mountain gorillas ( Gorilla) Tj ETQq0 0 C	) rgBT /Ov	erlock 10 Tf 5
119	Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring. Neuroscience, 2017, 340, 501-514.	2.3	35
120	Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 800-808.	1.4	35
121	Sex Steroid Levels and <scp>AD</scp> â€Like Pathology in 3x <scp>T</scp> g <scp>AD</scp> Mice. Journal of Neuroendocrinology, 2013, 25, 131-144.	2.6	34
122	Neuropathological correlates of amyloid PET imaging in Down syndrome. Developmental Neurobiology, 2019, 79, 750-766.	3.0	34
123	Galanin receptor over-expression within the amygdala in early Alzheimer's disease:. Journal of Chemical Neuroanatomy, 2002, 24, 109-116.	2.1	33
124	Galanin plasticity in the cholinergic basal forebrain in Alzheimer's disease and transgenic mice. Neuropeptides, 2005, 39, 233-237.	2,2	33
125	Galanin Hyperinnervation Upregulates Choline Acetyltransferase Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Neurodegenerative Diseases, 2008, 5, 228-231.	1.4	33
126	Endogenous Galanin Protects Mouse Hippocampal Neurons Against Amyloid Toxicity in vitro via Activation of Galanin Receptor-2. Journal of Alzheimer's Disease, 2011, 25, 455-462.	2.6	33

#	Article	IF	Citations
127	Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease. Neurobiology of Aging, 2017, 54, 133-143.	3.1	33
128	Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer's Disease. Neurodegenerative Diseases, 2010, 7, 139-142.	1.4	32
129	Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology. Neurobiology of Disease, 2019, 132, 104540.	4.4	32
130	Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia. Acta Neuropathologica, 2019, 137, 413-436.	7.7	32
131	Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 111-117.	2.1	31
132	Tenascin-C Is Associated with Cored Amyloid- $\hat{l}^2$ Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. Journal of Neuropathology and Experimental Neurology, 2016, 75, 868-876.	1.7	31
133	Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 246-259.	1.7	31
134	Rac1b Increases with Progressive Tau Pathology within Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease. American Journal of Pathology, 2012, 180, 526-540.	3.8	30
135	Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees. Journal of Comparative Neurology, 2018, 526, 2921-2936.	1.6	30
136	Astrocytic changes with aging and Alzheimer's diseaseâ€type pathology in chimpanzees. Journal of Comparative Neurology, 2019, 527, 1179-1195.	1.6	30
137	Cortical pyroglutamate amyloid- $\hat{l}^2$ levels and cognitive decline in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 12-19.	3.1	29
138	Braak stage and trajectory of cognitive decline in noncognitively impaired elders. Neurobiology of Aging, 2016, 43, 101-110.	3.1	28
139	Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2017, 55, 159-166.	3.1	28
140	Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer's disease. Journal of Neuroinflammation, 2020, 17, 58.	7.2	28
141	Editorial (Thematic Issue: The Link between Alzheimer's Disease and Down Syndrome. A Historical) Tj ETQq1 1 0	.784314 r 1.4	gBT_/Overlock
142	Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome. Current Alzheimer Research, 2015, 13, 84-96.	1.4	27
143	Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiology of Aging, 2016, 42, 80-90.	3.1	25
144	Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. Alzheimer's Research and Therapy, 2018, 10, 90.	6.2	23

#	Article	IF	Citations
145	Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study. Brain Injury, 2016, 30, 1399-1413.	1.2	21
146	Gene Profiling of Nucleus Basalis Tau Containing Neurons in Chronic Traumatic Encephalopathy: A Chronic Effects of Neurotrauma Consortium Study. Journal of Neurotrauma, 2018, 35, 1260-1271.	3.4	21
147	Effect of Neocortical and Hippocampal Amyloid Deposition upon Galaninergic and Cholinergic Neurites in AÎ <sup>2</sup> PPswe/PS1ΔE9 Mice. Journal of Alzheimer's Disease, 2011, 25, 491-504.	2.6	19
148	Long-term plastic changes in galanin innervation in the rat basal forebrain. Neuroscience, 2002, 115, 787-795.	2.3	18
149	Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. Molecular Neurodegeneration, 2020, 15, 68.	10.8	18
150	Braak Stage, Cerebral Amyloid Angiopathy, and Cognitive Decline in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 189-197.	2.6	18
151	Neuron loss associated with age but not Alzheimer's disease pathology in the chimpanzee brain. Philosophical Transactions of the Royal Society B: Biological Sciences, 2020, 375, 20190619.	4.0	17
152	Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. International Journal of Physiology, Pathophysiology and Pharmacology, 2012, 4, 115-27.	0.8	17
153	Cognitive Domain Dispersion Association with Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2017, 58, 575-583.	2.6	16
154	Exosome release and cargo in Down syndrome. Developmental Neurobiology, 2019, 79, 639-655.	3.0	15
155	Tau pathology in the medial temporal lobe of athletes with chronic traumatic encephalopathy: a chronic effects of neurotrauma consortium study. Acta Neuropathologica Communications, 2019, 7, 207.	5.2	15
156	Static and Dynamic Cognitive Reserve Proxy Measures: Interactions with Alzheimer's Disease Neuropathology and Cognition. , 2017, 07, .		13
157	Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome. Developmental Neurobiology, 2019, 79, 664-683.	3.0	13
158	Putative CSF protein biomarker candidates for amnestic mild cognitive impairment. Translational Neuroscience, 2010, 1, 2-8.	1.4	12
159	Association of early experience with neurodegeneration in aged primates. Neurobiology of Aging, 2011, 32, 151-156.	3.1	11
160	Frontal Cortex and Hippocampal & Diseases, 2017, 17, 235-241.	1.4	11
161	Comparative neuropathology in aging primates: A perspective. American Journal of Primatology, 2021, 83, e23299.	1.7	11
162	Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome. Acta Neuropathologica Communications, 2022, 10, .	5 <b>.</b> 2	11

#	Article	IF	CITATIONS
163	Cerebellar Calcium-Binding Protein and Neurotrophin Receptor Defects in Down Syndrome and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 645334.	3.4	10
164	Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders. Brain Communications, 2022, 4, .	3.3	10
165	Cholinergic profiles in the Goettingen miniature pig ( <i>Sus scrofa domesticus</i> ) brain. Journal of Comparative Neurology, 2017, 525, 553-573.	1.6	9
166	Telomeric alterations in the default mode network during the progression of Alzheimer's disease: Selective vulnerability of the precuneus. Neuropathology and Applied Neurobiology, 2021, 47, 428-440.	3.2	9
167	Maternal Choline Supplementation as a Potential Therapy for Down Syndrome: Assessment of Effects Throughout the Lifespan. Frontiers in Aging Neuroscience, 2021, 13, 723046.	3.4	8
168	Expression profiling of precuneus layer <scp>III</scp> cathepsin Dâ€immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability. Journal of Comparative Neurology, 2020, 528, 2748-2766.	1.6	5
169	Statistical considerations for assessing cognition and neuropathology associations in preclinical Alzheimer's disease. Biostatistics and Epidemiology, 2017, 1, 92-104.	0.4	4
170	Postnatal Cytoarchitecture and Neurochemical Hippocampal Dysfunction in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3414.	2.4	4
171	Co-expression network analysis of frontal cortex during the progression of Alzheimer's disease. Cerebral Cortex, 2022, 32, 5108-5120.	2.9	4
172	Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID. Translational Stroke Research, 2022, , 1.	4.2	4
173	Chronic traumatic encephalopathy and the nucleus basalis of Meynert. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 9-29.	1.8	2
174	Editorial: Down Syndrome, Neurodegeneration and Dementia. Frontiers in Aging Neuroscience, 2021, 13, 791044.	3.4	2
175	Connections of the hippocampal formation in humans: II. The endfolial fiber pathway. Journal of Comparative Neurology, 1997, 385, 352-371.	1.6	1
176	Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease., 0,.		1
177	Alzheimer's neuropathology in Down syndrome: From gestation to old age. , 2022, , 11-44.		0
178	Single cell gene expression profiling in Alzheimer's disease. Neurotherapeutics, 2006, 3, 302-318.	4.4	0